Clinical trials: Menstrually Related Migraine
Migraine
Safety and Tolerability of Frovatriptan to Prevention of Menstrually Associated Migraine (MAM) Headaches
In this open-label, multi-center study, patients were treated with frovatriptan for a maximum of 12 perimenstrual periods (PMPs).
- Trial name
- MAM (NCT01035983)
- Testing
- Frovatriptan 2.5 mg
- Where
- 5 sites in Germany, Hungary and 3 more
- Volunteers
- 550 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Migraine
A Multicenter Study to Evaluate the Efficacy of a 91-Day Extended Cycle Oral Contraceptive for Menstrually-Related Migraine Headaches
This study is being conducted to evaluate the efficacy of a 91-day extended cycle oral contraceptive compared to placebo for decreasing the frequency and severity of menstrually-related migraine headaches.
- Trial name
- NCT00781456
- Testing
- 91-day Levonorgestrel Oral Contraceptive
- Where
- 22 sites in United States
- Volunteers
- 109 people
- Sponsor
- Duramed Research
Migraine
Telcagepant for Prevention of Menstrually Related Migraine in Female Participants With Episodic Migraine (MK-0974-065)
This is a multicenter study to test the hypothesis that telcagepant is superior to placebo in preventing perimenstrual migraines as measured by mean monthly headaches during the entire treatment period.
- Trial name
- NCT01125774
- Testing
- Telcagepant
- Volunteers
- 4,548 people
- Sponsor
- Merck Sharp & Dohme LLC
Migraine
A Controlled Trial to Investigate the Efficacy and Safety of Frovatriptan to Prevent Menstrual Migraine
Although the predictability of an MRM headache attack lends itself to preventative treatment, there are currently no drugs specifically indicated for the prevention of MM.
- Trial name
- NCT00475514
- Testing
- Frovatriptan 2.5mg QD, Frovatriptan 2.5 mg BID
- Volunteers
- 500 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company